6 Amendments of Marco VALLI related to 2018/2210(DEC)
Amendment 5 #
Motion for a resolution
Paragraph 17 a (new)
Paragraph 17 a (new)
17a. Calls on the Commission to submit a plan as soon as possible to merge the common administrative functions of the agencies in order to cut spending and scale down administrative tasks that give no added value to the agencies' duties;
Amendment 12 #
Motion for a resolution
Paragraph 24 a (new)
Paragraph 24 a (new)
24a. Notes with concern that there have been frequent reports of harassment and abuse in some agencies; believes that effective prevention policies should be implemented and efficient procedures found to resolve the problems for victims; calls on the Commission actively to monitor the rules applied by agencies to prevent any form of mistreatment in- house;
Amendment 13 #
Motion for a resolution
Paragraph 25 a (new)
Paragraph 25 a (new)
25a. Considers the situation in EASO regarding procurement procedures to be unacceptable and calls on the Commission to bring more active oversight to bear on the procurement procedures carried out by agencies;
Amendment 20 #
Motion for a resolution
Paragraph 29 a (new)
Paragraph 29 a (new)
29a. Points out that the role of many agencies is to provide assessments and opinions on products and services for EU citizens; maintains that every expert's report provided by the agencies has to be based on the use of public data, as it is only in that way that reports can be checked and verified by the international scientific community; notes that, when making assessments, several agencies also use information that is protected as a trade secret; believes that agencies should publish all the sources that they use for their assessments, even those covered by trade secrecy, when giving opinions on products which might adversely affect the health of EU citizens;
Amendment 21 #
Motion for a resolution
Paragraph 33
Paragraph 33
33. Notes the agreement reached at the General Affairs Council of 20 November 2017 to move the European Medicines Agency (EMA) and the European Banking Authority (EBA) from London to Amsterdam and Paris respectively; believes, as regards the European Medicines Agency, that the fact that the final decision was brought about and adopted by drawing lots undermined the credibility of the selection methods used, since objective and substantive considerations were relegated to the background; believes that every decision concerning agency headquarters should factor in an accurate assessment of costs and benefits; deplores the fact that Parliament is only marginally involved in agreements of this kind; notes with concern the potential impact of the UK’s withdrawal from the Union on these agencies, in terms of future costs and loss of expertise, creating a risk to business continuity; notes moreover the possible impact on the revenue and activities of several non-London -based agencies; calls on the agencies to prepare to mitigate any potential risks that may follow and report to the discharge authority on the implementation of such preparatory measures;
Amendment 22 #
Motion for a resolution
Paragraph 33 a (new)
Paragraph 33 a (new)
33a. Notes with concern that some agencies continue to have dual operational and administrative headquarters; considers it essential that dual headquarters not offering any operational added value should be done away with at the earliest opportunity;